Literature DB >> 7922989

Radioprotection of the rat small intestine with topical WR-2721.

J P Delaney1, M E Bonsack, I Felemovicius.   

Abstract

BACKGROUND: The classic radioprotectant WR-2721 has been shown to reduce the severity of small bowel injury when administered systemically shortly before irradiation is delivered. This study tested the possibility that WR-2721 could provide protection when applied topically to intestinal mucosa. The second question addressed was the influence of pH on the effectiveness of this agent.
METHODS: The model used involved irradiation of exteriorized rat small bowel. A length of intestine was compartmentalized. The various individual segments were filled with a lumenal Tris buffer (pH 9), WR-2721, or a combination of these two, then irradiated with 1100 cGy. The animals were sacrificed 5 days later. Surviving crypt cells and mucosal height were the criteria used to quantitate mucosal injury.
RESULTS: The pH 9 buffer alone provided a small (16%) but significant preservation of crypt cell numbers. WR-2721 improved crypt survival by 54% at neutral pH, 83% at pH 9.
CONCLUSIONS: These data indicate that WR-2721, when applied topically to the small bowel mucosa of the rat before irradiation, provides substantial protection against radiation damage. The degree of benefit is amplified greatly when the drug is in an alkaline medium.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7922989     DOI: 10.1002/1097-0142(19941015)74:8<2379::aid-cncr2820740825>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.

Authors:  C R Culy; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis.

Authors:  Konstantinos H Katsanos; Evangelos Briasoulis; Pericles Tsekeris; Anna Batistatou; Maria Bai; Christos Tolis; Antonio Capizzello; Ioannis Panelos; Vasileios Karavasilis; Dimitrios Christodoulou; Epameinondas V Tsianos
Journal:  J Exp Clin Cancer Res       Date:  2010-06-10

3.  The role of amifostine on late normal tissue damage induced by pelvic radiotherapy with concomitant gemcitabine: an in vivo study.

Authors:  Fazilet Oner Dinçbaş; Didem Colpan Oksüz; Banu Atalar; Tuncay Altug; Sennur Ilvan; Nursal Gedik; Sevda Ozel; Sedat Koca
Journal:  Med Oncol       Date:  2008-11-30       Impact factor: 3.064

4.  Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.

Authors:  Nicole L Simone; Cynthia Ménard; Benjamin P Soule; Paul S Albert; Peter Guion; Sharon Smith; Denise Godette; Nancy S Crouse; Linda C Sciuto; Theresa Cooley-Zgela; Kevin Camphausen; C Norman Coleman; Anurag K Singh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-12       Impact factor: 7.038

5.  Intestinal radioprotection by vitamin E (alpha-tocopherol).

Authors:  I Felemovicius; M E Bonsack; M L Baptista; J P Delaney
Journal:  Ann Surg       Date:  1995-10       Impact factor: 12.969

Review 6.  The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects.

Authors:  G A Hospers; E A Eisenhauer; E G de Vries
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

7.  Local radiotherapy of exposed murine small bowel: apoptosis and inflammation.

Authors:  Andrea Polistena; Louis Banka Johnson; Salomé Ohiami-Masseron; Lena Wittgren; Sven Bäck; Charlotte Thornberg; Virgil Gadaleanu; Diya Adawi; Bengt Jeppsson
Journal:  BMC Surg       Date:  2008-01-03       Impact factor: 2.102

8.  Radiation enteropathy and leucocyte-endothelial cell reactions in a refined small bowel model.

Authors:  Louis Banka Johnson; Amjid Ali Riaz; Diya Adawi; Lena Wittgren; Sven Bäck; Charlotte Thornberg; Nadia Osman; Virgil Gadaleanu; Henrik Thorlacius; Bengt Jeppsson
Journal:  BMC Surg       Date:  2004-09-13       Impact factor: 2.102

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.